Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival. Furthermore, better outcomes in AO have been associated with 1p and 19q allelic loss.
INTRODUCTION
Anaplastic oligodendroglioma (AO) is a histologically distinct high-grade glioma that, when copopulated by neoplastic astrocytes, evokes a diagnosis of anaplastic oligoastrocytoma (AOA). 1 In recent years, the histologic criteria for the diagnosis of AO and AOA have liberalized, and as a result, the rate of diagnosis of both has increased. Today, up to 25% of newly diagnosed malignant gliomas are designated AO or AOA. 1 Standard treatment for AO and AOA consists of maximum surgical resection and radiotherapy (RT).
2 Although seldom curative, long survival is relatively common after such treatment. Median survival time is also relatively long, ranging from 3 to 5 years. 3 In North America, initial treatment for AO and AOA has often included chemotherapy with carmustine or procarbazine, lomustine, and vincristine (PCV). Chemotherapy at diagnosis has been justified on the basis of weak evidence of a survival benefit in studies of adjuvant carmustine for malignant glioma (trials populated largely by patients with glioblastoma). 4 Early chemotherapy for oligodendroglioma was reinforced by the discovery that AO and AOA are often chemotherapy sensitive, responding dramatically on computed tomography (CT) or magnetic resonance imaging (MRI) after exposure to PCV.
5,6
From the University of Calgary, Calgary, To test the hypothesis that PCV plus RT is a better initial treatment than RT alone for AO and AOA, the Radiation Therapy Oncology Group (RTOG) and four other oncology cooperatives undertook a randomized trial, which opened in 1994. Anticipating that chromosomal analysis might identify clinically important subsets of patients, 7 paraffin sections and blood were requested from all participants, and during the trial, the potential prognostic and predictive value of 1p and 19q allelic loss in AO was reported. 8, 9 
PATIENTS AND METHODS
Patients age Ն 18 years with a newly diagnosed, supratentorial AO or AOA were eligible. Anaplasia was based on an evaluation of the following five microscopic features: tumor cellularity, nuclear pleomorphism, mitotic activity, vascular proliferation, and necrosis. To be high grade, the tumor had to contain two anaplastic features, one of which was frequent mitoses or endothelial proliferation. To be an oligoastrocytoma, a 25% or greater oligodendroglioma component was required. The diagnosis was confirmed by central pathology review on all patients before random assignment. Eligible patients also had a Karnofsky performance score (KPS) of Ն 60 and adequate hematologic, pulmonary, renal, and hepatic function (absolute neutrophil count Ն 1.5 ϫ 10 9 /L, platelets Ն 150 ϫ 10 9 /L, oxygen diffusing capacity Ն 60%, serum creatinine Յ 1.5ϫ the upper limit of normal [ULN], total bilirubin Յ 1.5ϫ ULN, and liver function tests Ͻ 2ϫ ULN). Patients with other serious illnesses or pregnancy were ineligible. All study centers had institutional review board approval, and all patients consented in writing.
Study Design and Treatment
Patients were randomly assigned at RTOG headquarters within 8 weeks of surgical diagnosis to either PCV followed by focal RT (the experimental arm) or to RT alone (the control arm). Patients were stratified by age younger than 50 years versus 50 years or older, KPS of 60 to 70 versus Ն 80, and tumor grade of moderately anaplastic (two to three anaplastic features) versus highly anaplastic (four to five anaplastic features). Patients were required to begin the assigned treatment within 1 week of random assignment. Random assignment was performed by randomized permuted block within each stratification cell. In the experimental arm, up to four cycles of PCV were to be administered every 6 weeks before RT as follows: lomustine 130 mg/m 2 orally on day 1; procarbazine 75 mg/m 2 orally daily on days 8 to 21; and vincristine 1.4 mg/m 2 intravenously on days 8 and 29. Doses were calculated using actual body weight, reduced for toxicity, and not escalated. There was no upper limit on the dose of vincristine. Compliance was assessed by case reviews. Except for timing, RT was prescribed identically in the experimental and control arms. Patients randomly assigned to PCV plus RT were required to begin RT within 6 weeks of the final dose of chemotherapy. The total RT dose was 59.4 Gy in 33 fractions (1.8 Gy each), administered 5 days a week (Monday through Friday). Megavoltage irradiation (Ն 4 MV) was required. RT was planned using a gadolinium-enhanced MRI obtained within 2 weeks of random assignment and administered in two phases. The initial treatment field included the T2-weighted abnormality (ie, tumor plus edema) plus a 2-cm margin (50.4 Gy in 28 fractions). The boost field included the gadoliniumenhanced T1-weighted abnormality (ie, tumor) plus a 1-cm margin (9 Gy in five fractions). After a complete resection, the surgical cavity and edema with a 2-cm margin received the initial 50.4 Gy, and the cavity with a 1-cm margin received the final 9-Gy boost. Quality assurance was determined by case reviews.
Corticosteroid medications were permitted for cerebral edema, antiemetics were permitted for nausea or vomiting, and anticonvulsants were permitted for seizures. Deletions of chromosomes 1p and 19q were evaluated by fluorescence in situ hybridization analysis on tumor tissue sections as described elsewhere. 10 The primary end point was overall survival. Secondary end points were progression-free survival, frequency of severe (Ն grade 3) treatment toxicities, and quality of life. Survival measurements were made from the date of random assignment.
Surveillance and Follow-Up
Baseline examination included a CBC, pulmonary and biochemistry screening, either MRI or CT scan, and a complete physical and neurologic examination, including a Folstein Mini-Mental Status Examination. Quality of life was assessed as described by Mackworth et al. 10 During PCV, blood counts were checked weekly, and serum chemistries were checked before each cycle. During RT, patients were assessed weekly. Follow-up MRI or CT scans were performed before each cycle of PCV and 4 to 6 weeks after RT. Thereafter, scans were performed every 3 months during post-treatment year 1, every 4 months during year 2, every 6 months during years 3 to 5, and then annually. Follow-up laboratory evaluations, general and neurologic examinations, recording of corticosteroid requirements, and Mini-Mental Status Examination and quality-of-life assessments were scheduled similarly. Tumor progression was defined following Macdonald et al 11 (25% increase in tumor size by contrast-enhanced imaging, new lesions, or increasing corticosteroids). At progression, PCV was recommended for patients randomly assigned to RT, but otherwise, treatment at recurrence was discretionary. Second-line therapy was recorded. Toxicity was graded using the National Cancer Institute Common Toxicity Criteria (version 1). For RT toxicities, the RTOG acute morbidity criteria and the RTOG/European Organisation for Research and Treatment of Cancer late morbidity criteria were used.
Statistical Analysis
Overall and progression-free survival were analyzed by the KaplanMeier method with one-sided log-rank statistics. The study was designed to enroll 146 patients per arm, giving 80% power to detect a 50% increase in median survival time from 3.8 years in the control group to 5.7 years in the experimental group (hazard ratio [HR] for death ϭ 0.67), with a type I error rate of 0.05. Analyses were performed on a patient-eligible basis. The Cox proportional hazards model was fitted to adjust for stratification factors and other confounding clinical and genetic variables. Quality of life and neurologic function will be analyzed and reported separately.
RESULTS

Patients
From July 1994 to March 2002, 289 eligible patients from 76 institutions were randomly assigned to PCV plus RT (n ϭ 147) or RT alone (n ϭ 142); 50% were enrolled at 12 centers. Ten randomly assigned patients (five in each arm) were declared ineligible. In the experimental arm, the reasons for ineligibility were varied and included the following: pregnancy (n ϭ 1), missing baseline KPS (n ϭ 1), failure to obtain a planning MRI (n ϭ 1), incorrect diagnosis (n ϭ 1), and missing documentation of central pathology review (n ϭ 1). In the control arm, the reasons for ineligibility pertained to the diagnosis (n ϭ 2) or central review process. Sixty-nine percent of participants were under age 50 years, 60% were male, 88% had debulking surgery, 90% had a KPS Ն 80, and 74% had an AO or oligodendroglioma-dominant AOA. Moreover, the treatment groups were well balanced with respect to age, sex, KPS, imaging features, extent of resection, pure versus mixed histology, degree of anaplasia (moderate v high), and corticosteroid requirements at baseline (Table  1) . Unstained sections were available for fluorescence in situ hybridization analysis on 206 (71%) of 289 eligible patients; 1p and 19q deletion status was successfully ascertained in 201 patients (70%). The median duration of follow-up was 5.1 years (range, 3 to 93 months).
Patient Disposition and Treatment Delivery
The median time from diagnosis to the start of treatment was 5 weeks (range, 1 to 14 weeks) in the experimental arm and 6 weeks (range, 1 to 12 weeks) in the control arm (Table 2) . Chemotherapy was delivered per protocol in 72% of patients; minor or acceptable variations occurred in 17% and 6% of patients, respectively. In 4% of patients, PCV was either administered incorrectly or could not be verified. Fifty-four percent of patients received four cycles of PCV (wholly or partly), 22% received three, 10% received two, 12% received one, and 1% did not receive PCV despite being randomly assigned to PCV plus RT. Forty-eight percent of patients completed all four cycles of the dose-intensive PCV formulation used in the study. The reasons for stopping PCV were progression or death, toxicity, patient refusal, and physician preference. RT was administered per protocol or acceptably in 76% of PCV patients and in 82% of controls; unacceptable variations occurred in 6% and 8% of patients, respectively. Because of progression, death, or patient preference, RT was stopped in 10% of patients in the experimental arm and 5% of patients in the control arm. RT delivery could not be confirmed in 7% of patients in the experimental arm and 5% of patients in the control arm.
Survival
Thirty-eight months after the last patient was enrolled, 158 (55%) of 289 patients had died (75 of 147 patients in the experimental arm and 83 of 142 patients in the control arm). The unadjusted HR for death after PCV plus RT versus RT alone was 0.90 (95% CI, 0.66 to Abbreviations: PCV, procarbazine, lomustine, and vincristine; RT, radiotherapy; KPS, Karnofsky performance score; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma. ‫ء‬ Stratification factor at random assignment. † Tumor size ϭ estimated maximum cross-sectional area (largest diameter ϫ largest perpendicular diameter). 1.24; log-rank P ϭ .26), indicating that survival was not prolonged by PCV plus RT at diagnosis. The median survival time was 4.9 years in the PCV plus RT group and 4.7 years in the RT group (Table 3 and Fig  1) . Progression-free survival time was prolonged by PCV plus RT (HR ϭ 0.69; 95% CI, 0.52 to 0.91; log-rank P ϭ .004). Median progression-free survival time was 2.6 years with PCV plus RT compared with 1.7 years with RT alone (Fig 2) .
Safety
Patients randomly assigned to the experimental arm experienced significant toxicity. Sixty-five percent of patients (94 of 144 patients) had a grade 3 (48 of 144 patients, 33%) or 4 (46 of 144 patients, 32%) toxic reaction on PCV. The most frequent severe toxicities were hematologic (n ϭ 80), neurologic (cognitive or mood change and peripheral or autonomic neuropathy, n ϭ 19), GI (nausea and vomiting, n ϭ 13), hepatic (n ϭ 6), and dermatologic (n ϭ 6). One corticosteroid-dependent patient developed a severe pulmonary infection while neutropenic and died. Serious toxicities were uncommon during RT. Twelve patients (8%) in the PCV plus RT arm and seven patients (5%) in the RT arm had grade 3 or 4 toxicity (Table 4) . Late toxicities were uncommon, occurring in 4% and 5% of patients in the experimental and control groups, respectively. No instances of dementia or radionecrosis have been reported in either group. 
Treatment at Progression
For patients randomly assigned to RT, PCV at recurrence was recommended. In May 2005, 177 (61%) of 289 patients had experienced progression, including 76 (52%) of 147 patients in the experimental arm and 101 (71%) of 142 controls. Rates of salvage chemotherapy differed significantly between the groups. At progression, 81 (80%) of 101 patients assigned to RT received salvage chemotherapy compared with 29 (37%) of 76 patients assigned to PCV plus RT. In the control arm, the cytotoxics used at progression were PCV (n ϭ 21), temozolomide (n ϭ 10), both PCV and temozolomide (n ϭ 11), or neither PCV nor temozolomide (n ϭ 12) or were unspecified (n ϭ 27). In the experimental arm, a variety of cytotoxics was used, often temozolomide (n ϭ 14). Response to salvage chemotherapy was not recorded. Other therapies at progression included second surgery, focused reirradiation, and investigational maneuvers. Rates of second surgery also differed significantly between the groups. Sixtyone (60%) of 101 patients in the control group had second surgery compared with 30 (39%) of 76 patients assigned to PCV plus RT. Whether differences in the intensity or effectiveness of treatment at recurrence had a disproportionately favorable influence on the overall survival of patients in the control group is open to speculation.
Chromosomal Analysis
Loss of 1p was detected in 109 (54%) of 202 informative patients, including 50 (50%) of 101 patients in the PCV plus RT group and 59 (58%) of 101 patients in the RT group (Table 5) . Loss of 19q was found in 126 (61%) of 205 informative patients, including 62 (61%) of 102 patients in the PCV plus RT group and 64 (62%) of 103 patients in the RT group. Combined loss of 1p and 19q was detected in 93 (46%) of 201 patients, including 43 (43%) of 100 patients in the PCV plus RT group and 50 (50%) of 101 patients in the RT group. Combined loss was more frequent in pure tumors (57% for AO v 14% for AOA, P Ͻ .001). Patients whose tumors had combined 1p and 19q loss also had longer survival time. The HR for death for 1p-and 19q-deleted patients was significantly reduced compared with all other patients (HR ϭ 0.31; 95% CI, 0.20 to 0.47; log-rank P Ͻ .001; median overall survival time, not reached v 2.8 years, respectively; Fig 3) . Similarly, combined loss of 1p and 19q was associated with a significantly lower risk of tumor progression compared with no loss (HR ϭ 0.44; 95% CI, 0.32 to 0.62; log-rank P Ͻ .001; median progression-free survival time, 4.0 v 1.3 years, respectively).
There was no effect of treatment on survival analyzed by genotype (Fig 4) . For 1p-and 19q-deleted patients, the HR for death after PCV plus RT versus RT alone was 0.81 (95% CI, 0.40 to 1.65; log-rank P ϭ .28; median survival time, not reached v 6.6 years, respectively). Similarly, for patients with tumors with other genotypes, treatment had no effect on survival (HR ϭ 0.91; 95% CI, 0.58 to 1.42; log-rank P ϭ .33; median survival time, 2.7 years for PCV plus RT v 2.8 years for RT only). The lower risk of progression after PCV plus RT compared with RT only was statistically significant only for the patients with both 1p and 19q deletions (HR ϭ 0.42; 95% CI, 0.24 to 0.75; log-rank P ϭ .001; median progression-free survival time, not reached v 2.6 years, respectively; Fig 5) . For the other patients, initial treatment had no significant effect on the risk of progression (HR ϭ 0.78; 95% CI, 0.51 to 1.18; log-rank P ϭ .12; median progression-free survival time, 1.4 years for PCV plus RT v 1.0 years for RT only).
Cox Multivariate Regression Analysis
The influence of genetic and clinical variables on survival was analyzed in the Cox proportional hazards models with assigned treatment, age, KPS, and number of anaplastic features as fixed covariates. Loss of 1p, loss of 19q, younger age, normal neurologic function, moderate anaplasia, debulking surgery, and unifocality on baseline imaging were independently associated with longer overall survival time, whereas sex, race, tumor histology, and corticosteroid use were not. Loss of 1p, PCV therapy, younger age, moderate anaplasia, and unifocality predicted longer progression-free survival time. Loss of 19q was not associated with progression-free survival in the final Cox model.
DISCUSSION
This study, conceived in the early 1990s, tested the hypothesis that a dose-intensive PCV formulation administered immediately before RT would prolong the survival of patients with newly diagnosed AO and AOA compared with RT alone, which was then the standard of care for all types of anaplastic glioma. The idea that a recognizable subtype of malignant glioma might be cured by intensive initial therapy was an exciting prospect in 1994. 12, 13 Instead, this study and a similar trial in Europe 14 demonstrate that PCV plus RT at diagnosis is not a better initial management strategy for AO and AOA compared with RT alone. Because most patients in the control group received PCV or similar chemotherapy at progression, one could argue that this study actually tested the hypothesis that intense initial therapy with PCV and RT is superior to sequential treatment for AO and AOA; it is not. This result stands in sharp contrast to the findings in the study by Stupp et al, 15 in which the survival of patients with glioblastoma was prolonged by temozolomide plus RT at diagnosis. Why might early chemotherapy be effective for glioblastoma, a chemotherapy-resistant cancer, but not oligodendroglioma, a chemotherapy-sensitive cancer? Two possibilities come to mind. First, compared with glioblastoma, AO and AOA have favorable natural histories, which is a characteristic that may be a more important determinant of survival than any combination or sequence of noncurative therapies, like PCV and RT. Second, temozolomide, which also alkylates DNA, is well tolerated compared with PCV. Temozolomide can be administered daily during RT without significant myelosuppression, 15 whereas toxicity precludes chemoradiotherapy with PCV. The fact that progression-free survival was prolonged by adding PCV to RT at diagnosis suggests that early chemotherapy may have the potential to improve overall survival as well. Such potential might be realized by a drug like temozolomide, which is less toxic and can be administered daily with RT. Indeed, temozolomide has significant antioligodendroglioma activity. 16, 17 During the trial, retrospective studies drew attention to a possible association between 1p and 19q allelic loss and radiographic response to PCV, durable response to PCV, long progression-free survival after RT, and long overall survival in patients with AO. 8, 9, [18] [19] [20] [21] [22] [23] In this study, tumor tissue was available for analysis in 71% of patients. Codeletion of 1p and 19q was detected in 46% of assessable patients. Patients whose tumors harbored a codeletion of 1p and 19q lived far longer than all other patients. In the Cox multivariate regression analysis, 1p loss and 19q loss were independent predictors of overall survival, suggesting that tumors with 1p or 19q loss, but especially a codeletion, have a more favorable natural history, response to treatment, or both. Indeed, tumors with 1p and 19q codeletion are a clinically and biologically distinct subgroup of oligodendrogliomas.
A post hoc analysis of the interaction of treatment and genotype showed that treatment assignment had no effect on survival. For both the 1p and 19q codeleted patients and the other patients, adding PCV to RT at diagnosis did not prolong life. Of note, the progression-free survival benefit observed in patients randomly assigned to PCV plus RT was only statistically significant in the 1p and 19q subset. This finding provides further evidence that loss of 1p and 19q is both a predictive and prognostic marker in AO and AOA, supporting earlier results linking this codeletion with radiographic response to PCV. 8 Whether 1p and 19q loss is a relative or absolute marker of chemotherapy sensitivity is unresolved by these data.
This study successfully examined the treatment of an uncommon brain tumor, demonstrating that multimodality treatment at diagnosis is no more effective in prolonging survival than a measured approach to initial treatment, using RT and chemotherapy sequentially, as needed. Although progression-free survival was prolonged by early intensive treatment, PCV plus RT at diagnosis was accompanied by substantial chemotherapy-related toxicity. 
